Product Information
IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $2.7670 per EA under NDC 43598034530. Its NADAC has been published 342 times since Oct 17, 2018.
FDA first approved this application on Aug 13, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598034530
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
4/23/2025
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA206547FDA Approved
8/13/2018
TE Code
AB
On Market Since
8/13/2018
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 342 times since Oct 17, 2018, and over the history we have for it it has declined 84.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7670 per EA |
|---|---|
| All-time high | $20.4013 (Jan 16, 2019) |
| All-time low | $1.4080 (Aug 23, 2023) |
| Median price | $3.4068 |
| Average price | $5.6696 |
| Largest weekly change | +100.9% (Mar 18, 2020) |
| Weeks tracked | 342 |
| Tracking since | Oct 17, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+47.3%
5Y
-28.4%
All
-84.3%
Last surveyed Apr 30, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Imatinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Dr. Reddy's Laboratories Inc., is $2.7670 per EA (NDC 43598034530), effective Apr 30, 2025.
How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 84.3%. It has been tracked across 342 weekly CMS publications since Oct 17, 2018.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?
Since Oct 17, 2018, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $20.4013 (Jan 16, 2019), with a median of $3.4068 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.6771 per EA — about 3% below IMATINIB MESYLATE 400 MG TAB.
Who manufactures IMATINIB MESYLATE 400 MG TAB?
IMATINIB MESYLATE 400 MG TAB (NDC 43598034530) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.